Global Migraine Treatment Market
حجم السوق بالمليار دولار أمريكي
CAGR :
% 
 فترة التنبؤ |
2022 –2029 |
 حجم السوق (السنة الأساسية) |
USD 2.38 Billion |
 حجم السوق (سنة التنبؤ) |
USD 4.67 Billion |
 CAGR |
% |
| Major Markets Players |
>السوق العالمية لعلاج الصداع النصفي، حسب الأنواع (العرضية، الصداع النصفي مع الهالة، المزمن وغيرها)، العلاج (العلاج الحاد/الإجهاضي، العلاج الوقائي/الوقائي، العلاجات والأجهزة غير الدوائية)، طريق الإعطاء (عن طريق الفم، الحقن، بخاخات الأنف وغيرها)، نوع المنتج (وصفة طبية وبدون وصفة طبية)، النوع (علامة تجارية وعام ، المستخدم النهائي (المستشفيات، العيادات، الرعاية المنزلية، وغيرها)، قناة التوزيع (صيدليات المستشفيات، صيدليات التجزئة، الصيدليات عبر الإنترنت وغيرها) - اتجاهات الصناعة والتوقعات حتى عام 2029
تحليل السوق والحجم
الصداع النصفي هو مرض شائع يصيب الدماغ وقد يكون منهكاً. ويمثل الصداع 4.4% من جميع زيارات العيادات العامة، ونحو 5% من جميع حالات الدخول إلى المستشفيات الطبية، وأكثر من 20% من استشارات العيادات الخارجية لطب الأعصاب. ويصيب الصداع النصفي نحو 20% من الناس في مرحلة ما من حياتهم، وتكشف الأبحاث الوبائية أن 4.5% من سكان أوروبا الغربية يعانون من الصداع لمدة 15 يوماً على الأقل في الشهر، في حين تشير الدراسات العالمية إلى أن نحو 1% من سكان العالم يعانون من الصداع النصفي المزمن.
تحلل شركة Data Bridge Market Research أن سوق علاج الصداع النصفي الذي بلغ 2.38 مليار دولار أمريكي في عام 2021، سيرتفع إلى 4.67 مليار دولار أمريكي بحلول عام 2029، ومن المتوقع أن يخضع لمعدل نمو سنوي مركب بنسبة 8.80٪ خلال الفترة المتوقعة من 2022 إلى 2029. بالإضافة إلى رؤى السوق مثل القيمة السوقية ومعدل النمو وشرائح السوق والتغطية الجغرافية واللاعبين في السوق وسيناريو السوق، يتضمن تقرير السوق الذي أعده فريق Data Bridge Market Research أيضًا تحليلًا متعمقًا من الخبراء وعلم الأوبئة للمرضى وتحليل خطوط الأنابيب وتحليل الأسعار والإطار التنظيمي.
نطاق التقرير وتقسيم السوق
|
تقرير القياس |
تفاصيل |
|
فترة التنبؤ |
2022 إلى 2029 |
|
سنة الأساس |
2021 |
|
سنوات تاريخية |
2020 (قابلة للتخصيص حتى 2014 - 2019) |
|
وحدات كمية |
الإيرادات بالمليارات من الدولارات الأمريكية، الأحجام بالوحدات، التسعير بالدولار الأمريكي |
|
القطاعات المغطاة |
الأنواع (المتقطعة، والصداع النصفي مع الهالة، والصداع المزمن وغيرها)، والعلاج (العلاج الحاد/الإجهاضي، والعلاج الوقائي/الوقائي، والعلاجات والأجهزة غير الدوائية)، وطريقة الإعطاء (عن طريق الفم، والحقن، وبخاخات الأنف وغيرها)، ونوع المنتج (الوصفة الطبية وغير ذلك)، والنوع (العلامة التجارية والنوع العام)، والمستخدم النهائي (المستشفيات والعيادات والرعاية المنزلية وغيرها)، وقناة التوزيع (صيدليات المستشفيات، وصيدليات التجزئة، والصيدليات عبر الإنترنت وغيرها) |
|
الدول المغطاة |
الولايات المتحدة وكندا والمكسيك في أمريكا الشمالية وألمانيا وفرنسا والمملكة المتحدة وهولندا وسويسرا وبلجيكا وروسيا وإيطاليا وإسبانيا وتركيا وبقية دول أوروبا في أوروبا والصين واليابان والهند وكوريا الجنوبية وسنغافورة وماليزيا وأستراليا وتايلاند وإندونيسيا والفلبين وبقية دول آسيا والمحيط الهادئ (APAC) في منطقة آسيا والمحيط الهادئ (APAC) والمملكة العربية السعودية والإمارات العربية المتحدة وجنوب أفريقيا ومصر وإسرائيل وبقية دول الشرق الأوسط وأفريقيا (MEA) كجزء من الشرق الأوسط وأفريقيا (MEA) والبرازيل والأرجنتين وبقية دول أمريكا الجنوبية كجزء من أمريكا الجنوبية |
|
الجهات الفاعلة في السوق المشمولة |
Pfizer Inc. (الولايات المتحدة)، Eli Lilly and Company (الولايات المتحدة)، Amgen Inc. (الولايات المتحدة)، GlaxoSmithKline plc. (المملكة المتحدة)، Novartis AG (سويسرا)، Bayer AG (ألمانيا)، Allergan (أيرلندا)، Abbott (الولايات المتحدة)، Allodynic Therapeutics, LLC (الولايات المتحدة)، AOBiome (الولايات المتحدة)، AstraZeneca (المملكة المتحدة)، Aurobindo Pharma USA (الولايات المتحدة)، Bausch Health Companies Inc. (كندا)، Biohaven Pharmaceuticals (الولايات المتحدة)، Boehringer Ingelheim International GmbH (ألمانيا)، Catalent, Inc (الولايات المتحدة)، Dr. Reddy's Laboratories Ltd. (الهند)، Impel Pharmaceuticals Inc. (الولايات المتحدة)، H. Lundbeck A/S (الدنمارك)، Merck & Co., Inc (الولايات المتحدة) |
|
فرص السوق |
|
تعريف السوق
الصداع النصفي هو مرض عصبي مدمر يتميز بنوبات ألم نابضة حادة متكررة في الرأس يمكن أن تستمر لأكثر من ثلاثة أيام. يمكن أن يستمر الصداع، الذي يكون عادة من جانب واحد، من أربع ساعات إلى ثلاثة أيام. غالبًا ما ترتبط أعراض أخرى بالألم مثل الغثيان، وزيادة الحساسية للصوت (رهاب الصوت)، والتقيؤ، وزيادة الحساسية للضوء (رهاب الضوء)، والوخز أو الخدر في الأطراف أو الساقين، والتعرق، والإسهال .
ديناميكيات سوق علاج الصداع النصفي
السائقين
• زيادة في انتشار الصداع النصفي وتشخيصه
إن أحد العوامل الرئيسية التي تدفع توسع السوق هو الزيادة الهائلة في حالات الصداع النصفي. كما يستفيد السوق من سياسات السداد المحسنة لعلاجات الصداع النصفي والطلب المتزايد على الأدوية الدقيقة. إن الطلب المتزايد على أجهزة تحفيز الأعصاب الكهربائية لعلاج الصداع النصفي والموافقة المتوقعة على فئات جديدة من الأدوية في المراحل المتأخرة ذات الفعالية السريرية الأعلى، مثل إدخال الأجسام المضادة وحيدة النسيلة للببتيد المرتبط بجين الكالسيتونين (CGRP)، تعمل على دفع نمو السوق.
• تم تحقيق تقدم كبير في العلاج الوقائي للصداع النصفي المزمن
إن التطورات الكبيرة التي حدثت يجب أن تعيد النظر في الأساليب المتبعة في التعامل مع هذا المرض المدمر وتمكننا من البقاء على اطلاع دائم ومواصلة البحث العلمي السريري مع الأخذ في الاعتبار أن استراتيجية إدارة سريرية وعلمية مشتركة فقط هي التي ستحسن من اكتشاف الصداع النصفي المزمن. وهذا يميز بين النمط الظاهري والعلامات البيولوجية، ويلقي الضوء على مجالات الحوكمة السريرية المهملة. ويتعين علينا ضمان استغلال البدائل العلاجية الجديدة والمتطورة، مثل الأجسام المضادة أحادية النسيلة OBT-A ومضادات CGRP، إلى أقصى إمكاناتها ضمن ثقافة وقائية أوسع لتقليل التكاليف الشخصية والمجتمعية والاقتصادية لهذا المرض القاتل بشكل كبير.
- تزايد الوعي بشأن الصداع النصفي
إن الوعي المتزايد بالصداع النصفي وخيارات العلاج المتعددة المتاحة هي المحركات الأساسية لنمو سوق علاج الصداع النصفي العالمي في المستقبل القريب. تحاول عدد من المنظمات، مثل الجمعية الأمريكية للصداع النصفي والصداع، زيادة الوعي بالصداع النصفي من خلال تطوير البرامج وتقديم المساعدة للمرضى من أجل زيادة المعرفة حول المرض وأمراض الصداع الأخرى. سيستثمر الكثير من البائعين في البحث والتطوير لأدوية الصداع النصفي نتيجة للعدد المتزايد من حالات الصداع النصفي والطلبات غير الملباة في سوق علاج الصداع النصفي العالمي. ونتيجة لذلك، من المتوقع أن ينمو سوق أدوية الصداع النصفي العالمي في الفترة المتوقعة من 2022 إلى 2029.
فرص
يتضمن علاج الصداع النصفي ميزات مثل زيادة الاستثمار في البحث والتطوير مما يؤدي إلى إنتاج منتجات جديدة، مما سيؤدي إلى قيام الشركات المصنعة بطرح منتجات جديدة في السوق، وزيادة الطلب، وزيادة التقدم التكنولوجي لعلاج الصداع النصفي الحاد. هناك العديد من الدراسات البحثية الجارية الآن، والتي من المرجح أن تمنح المنتجين ميزة تنافسية في تطوير أدوية علاج الصداع النصفي الجديدة والمبتكرة والمحسنة وغيرها من الفرص في سوق علاج الصداع النصفي.
القيود/التحديات
ومع ذلك، من المتوقع أن تعمل العلاجات البديلة مثل المعالجة المثلية والقيود المفروضة على علاجات الصداع النصفي الحالية، وانخفاض الزيارات السريرية والعلاج الإجرائي للصداع النصفي بسبب معايير التباعد الاجتماعي على كبح نمو السوق في الفترة المتوقعة من 2022 إلى 2029.
يقدم تقرير سوق علاج الصداع النصفي هذا تفاصيل عن التطورات الحديثة الجديدة، واللوائح التجارية، وتحليل الاستيراد والتصدير، وتحليل الإنتاج، وتحسين سلسلة القيمة، وحصة السوق، وتأثير اللاعبين المحليين والمحليين في السوق، وتحليل الفرص من حيث جيوب الإيرادات الناشئة، والتغيرات في لوائح السوق، وتحليل نمو السوق الاستراتيجي، وحجم السوق، ونمو سوق الفئات، ومنافذ التطبيق والهيمنة، وموافقات المنتجات، وإطلاق المنتجات، والتوسعات الجغرافية، والابتكارات التكنولوجية في السوق. للحصول على مزيد من المعلومات حول سوق علاج الصداع النصفي، اتصل بـ Data Bridge Market Research للحصول على موجز محلل، وسيساعدك فريقنا في اتخاذ قرار سوقي مستنير لتحقيق نمو السوق.
تأثير كوفيد-19 على سوق علاج الصداع النصفي
تشير العلامات العصبية لمرض كوفيد-19 إلى دخول الفيروس إلى الجهاز العصبي عبر الأخدود الشمي أو الدورة الدموية. وقد ارتبطت وفيات كوفيد-19 بأمراض القلب والرئة في العديد من الدراسات. علاوة على ذلك، يتسبب الصداع النصفي في عبء أكبر من الاضطرابات الوعائية، مما يعرض المصابين بالصداع النصفي لخطر أكبر من نتائج كوفيد-19 السيئة . يمكن أن تحدث نوبة الصداع النصفي بسبب أعراض كوفيد-19 الحادة مثل الحمى وصعوبة النوم والجفاف. وُصفت نوبات الصداع النصفي بأنها نابضة أو ضاغطة أو طعنية بطبيعتها، وكانت في الغالب ثنائية الجانب، وتستمر لفترة أطول، ومقاومة للتسكين، وأكثر شيوعًا عند الذكور. وهذا يجعل المصابين بالصداع النصفي عرضة بشكل خاص للعواقب غير المباشرة وطويلة الأمد للوباء، مثل انخفاض الحالة المزاجية والإرهاق بعد الفيروس والقلق.
التطورات الأخيرة
- وفقًا لشركة Biohaven Pharmaceutical Holding Company Ltd. وشركة Pfizer Inc.، حصل Rimegepant، وهو مضاد لمستقبلات الببتيد المرتبط بجين الكالسيتونين (CGRP)، على رأي إيجابي من لجنة المنتجات الطبية للاستخدام البشري (CHMP) التابعة لوكالة الأدوية الأوروبية (EMA) في فبراير 2022. تم اقتراح جرعة 75 مجم من Rimegepant (متوفرة كقرص يذوب في الفم) للحصول على ترخيص التسويق لعلاج الصداع النصفي الحاد مع أو بدون هالة عند البالغين والعلاج الوقائي للصداع النصفي العرضي عند البالغين الذين يعانون من أربع نوبات صداع نصفي على الأقل شهريًا.
- في يناير 2022، أصبح Elyxyb (محلول سيليكوكسيب عن طريق الفم) سائلًا جديدًا سريع المفعول من BioDelivery Sciences. وهو أحد أول العلاجات الفموية الجاهزة للاستخدام المعتمدة من إدارة الغذاء والدواء للأفراد الذين يعانون من الصداع النصفي الحاد مع أو بدون هالة.
نطاق سوق علاج الصداع النصفي العالمي
يتم تقسيم سوق علاج الصداع النصفي على أساس النوع والعلاج وطريقة الإدارة والمنتج وقناة التوزيع والمستخدم النهائي. سيساعدك النمو بين هذه القطاعات على تحليل قطاعات النمو الضئيلة في الصناعات وتزويد المستخدمين بنظرة عامة قيمة على السوق ورؤى السوق لمساعدتهم على اتخاذ قرارات استراتيجية لتحديد تطبيقات السوق الأساسية.
أنواع
علاج
- العلاج الحاد/الإجهاضي
- العلاج الوقائي/الوقائي
- العلاجات والأجهزة غير الدوائية
طريق الإدارة
- شفوي
- الحقن الوريدي
منتج
- روشتة
- دون وصفة طبية
يكتب
- العلامة التجارية
- نوعي
المستخدم النهائي
- المستشفيات
- العيادات
- الرعاية المنزلية
- آحرون
قناة التوزيع
- الصيدليات الموجودة في المستشفيات
- صيدليات التجزئة
- الصيدليات على الإنترنت
- آحرون
تحليل/رؤى إقليمية لسوق علاج الصداع النصفي
يتم تحليل سوق علاج الصداع النصفي وتوفير رؤى حجم السوق والاتجاهات حسب البلد والنوع والعلاج وطريقة الإدارة والمنتج وقناة التوزيع والمستخدم النهائي كما هو مذكور أعلاه.
الدول التي يغطيها تقرير سوق علاج الصداع النصفي هي الولايات المتحدة وكندا والمكسيك في أمريكا الشمالية وألمانيا وفرنسا والمملكة المتحدة وهولندا وسويسرا وبلجيكا وروسيا وإيطاليا وإسبانيا وتركيا وبقية أوروبا في أوروبا والصين واليابان والهند وكوريا الجنوبية وسنغافورة وماليزيا وأستراليا وتايلاند وإندونيسيا والفلبين وبقية دول آسيا والمحيط الهادئ (APAC) في منطقة آسيا والمحيط الهادئ (APAC) والمملكة العربية السعودية والإمارات العربية المتحدة وجنوب إفريقيا ومصر وإسرائيل وبقية دول الشرق الأوسط وأفريقيا (MEA) كجزء من الشرق الأوسط وأفريقيا (MEA) والبرازيل والأرجنتين وبقية دول أمريكا الجنوبية كجزء من أمريكا الجنوبية.
تُعَد أمريكا الشمالية منطقة مهيمنة في سوق علاج الصداع النصفي العالمي. ويُعد وجود قطاع صيدلاني راسخ في المنطقة سببًا مهمًا في المكانة القوية التي تحتلها أمريكا الشمالية في سوق علاج الصداع النصفي العالمي. وعلاوة على ذلك، نظرًا للفهم الكبير لمخاطر الصداع النصفي وكيف يؤثر على جودة الحياة، هناك حاجة كبيرة لأدوية الصداع النصفي في المنطقة.
يقدم قسم الدولة في التقرير أيضًا عوامل التأثير الفردية على السوق والتغييرات في التنظيم في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. نقاط البيانات مثل تحليل سلسلة القيمة المصب والمصب، والاتجاهات الفنية وتحليل قوى بورتر الخمس، ودراسات الحالة هي بعض المؤشرات المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. أيضًا، يتم النظر في وجود وتوافر العلامات التجارية العالمية والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية، وتأثير التعريفات الجمركية المحلية وطرق التجارة أثناء تقديم تحليل توقعات لبيانات الدولة.
نمو البنية التحتية للرعاية الصحية والقاعدة المركبة واختراق التكنولوجيا الجديدة
يوفر لك سوق علاج الصداع النصفي أيضًا تحليلًا تفصيليًا للسوق لكل بلد من حيث نمو الإنفاق على الرعاية الصحية للمعدات الرأسمالية، والقاعدة المثبتة لأنواع مختلفة من المنتجات لسوق علاج الصداع النصفي، وتأثير التكنولوجيا باستخدام منحنيات خط الحياة والتغييرات في سيناريوهات التنظيم الصحي وتأثيرها على سوق علاج الصداع النصفي. البيانات متاحة للفترة التاريخية 2010-2020.
تحليل المنافسة وحصة سوق علاج الصداع النصفي
يوفر المشهد التنافسي لسوق علاج الصداع النصفي تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور العالمي، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات فيما يتعلق بسوق علاج الصداع النصفي.
بعض اللاعبين الرئيسيين العاملين في سوق علاج الصداع النصفي هم:
- شركة فايزر (الولايات المتحدة)
- شركة إيلي ليلي (الولايات المتحدة)
- شركة أمجين (الولايات المتحدة)
- شركة جلاكسو سميث كلاين المحدودة (المملكة المتحدة)
- نوفارتيس أيه جي (سويسرا)
- شركة باير ايه جي (ألمانيا)
- أليرجان (أيرلندا)
- أبوت (الولايات المتحدة)
- شركة Allodynic Therapeutics, LLC (الولايات المتحدة)
- AOBiome (الولايات المتحدة)
- أسترازينيكا (المملكة المتحدة)
- أوروبيندو فارما الولايات المتحدة الأمريكية (الولايات المتحدة)
- شركات بوش الصحية المحدودة (كندا)
- شركة بيوهافن للأدوية (الولايات المتحدة)
- شركة بوهرينغر إنجلهايم الدولية المحدودة (ألمانيا)
- شركة كاتالنت (الولايات المتحدة)
- مختبرات الدكتور ريدي المحدودة (الهند)
- شركة إمبل للأدوية (الولايات المتحدة)
- H. Lundbeck A/S (الدنمارك)
- شركة ميرك وشركاه المحدودة (الولايات المتحدة)
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MIGRAINE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPES OF MIGRAINE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING PREVALENCE OF MIGRAINE
3.1.2 GROWING FEMALE POPULATION
3.1.3 DEVELOPMENT OF NOVEL DRUGS
3.1.4 RISING AWARENESS PROGRAMS
3.1.5 AVAILABILITY OF LARGE NUMBER OF GENERIC DRUGS
3.2 RESTRAINTS
3.2.1 RECALL OF DRUGS
3.2.2 ADVERSE EFFECTS OF DRUGS
3.3 OPPORTUNITIES
3.3.1 TECHNOLOGICAL ADVANCEMENTS FOR THE TREATMENT OF ACUTE MIGRAINE
3.3.2 INCREASING R&D INVESTMENT LEADING TO PIPELINE PRODUCTS
3.3.3 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS
3.4 CHALLENGES
3.4.1 USE OF ALTERNATIVE THERAPIES SUCH AS HOMEOPATHY
3.4.2 LIMITATIONS OF CURRENT MIGRAINE THERAPIES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EPIDEMIOLOGY
7 REIMBURSEMENT SCENARIO & REGULATION STATUS
7.1 REIMBURSEMENT SCENARIO
7.2 REGULATIONS
8 PIPELINE ANALYSIS
9 IMPACT OF COVID 19 PANDEMIC ON THE MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE
10.1 OVERVIEW
10.2 EPISODIC
10.3 MIGRAINE WITH AURA
10.4 CHRONIC
10.5 OTHERS
11 GLOBAL MIGRAINE TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 ACUTE/ABORTIVE TREATMENT
11.2.1 NONSPECIFIC THERAPIES
11.2.1.1 TRIPTANS
11.2.1.1.1 SUMATRIPTAN
11.2.1.1.2 RIZATRIPTAN
11.2.1.1.3 OTHERS
11.2.1.2 OPIATES/OPOIDS
11.2.1.2.1 VICODIN
11.2.1.2.2 OXYCONTIN
11.2.1.2.3 PERCOCET
11.2.1.2.4 OTHERS
11.2.1.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
11.2.1.3.1 ASPIRIN
11.2.1.3.2 IBUPROFEN
11.2.1.3.3 ACETAMINOPHEN
11.2.1.3.4 OTHERS
11.2.1.4 ERGOT ALKALOID
11.2.1.4.1 ERGOTAMINE
11.2.1.4.2 LASMIDITAN
11.2.1.4.3 DIHYDROERGOTAMINES
11.2.1.4.4 OTHERS
11.2.1.5 ANTI-NAUSEA
11.2.1.5.1 PROCHLORPERAZINE
11.2.1.5.2 METOCLOPRAMIDE
11.2.1.5.3 CHLORPROMAZINE
11.2.1.5.4 OTHERS
11.2.1.6 OTHERS
11.2.2 ADJUNCTIVE THERAPIES
11.2.2.1 ANTIEMETICS
11.2.2.2 SEDATIVES
11.2.2.3 OTHERS
11.2.3 OTHERS
11.2.3.1 INTRANASAL LIDOCAINE
11.2.3.2 STEROIDS
11.2.3.3 OTHERS
11.3 PREVENTIVE/PROPHYLACTIC TREATMENT
11.3.1 ANTICONVULSANTS
11.3.1.1 TOPAMAX (TOPIRAMATE)
11.3.1.2 TROKENDI (TOPIRAMATE)
11.3.1.3 DEPAKOTE (DIVALPROEX SODIUM)
11.3.1.4 QUDEXY XR (TOPIRAMATE)
11.3.1.5 OTHERS
11.3.2 CALCITONIN GENE-RELATED PEPTIDE THERAPY
11.3.2.1 ERENUMAB-AOOE
11.3.2.2 GALCANEZUMAB
11.3.2.3 FREMANEZUMAB-VFRM
11.3.2.4 OTHERS
11.3.3 SELECTIVE SEROTONIN RECEPTOR AGONISTS
11.3.3.1 SUMATRIPTAN
11.3.3.2 RIZATRIPTAN
11.3.3.3 ZOLMITRIPTAN
11.3.3.4 ELETRIPTAN
11.3.3.5 FROVATRIPTAN
11.3.3.6 NARATRIPTAN
11.3.3.7 ALMOTRIPTAN MALATE
11.3.3.8 OTHERS
11.3.4 ANTIDEPRESSANTS
11.3.4.1 AMITRIPTYLINE
11.3.4.2 NORTRIPTYLINE
11.3.4.3 OTHERS
11.3.5 NSAIDS
11.3.5.1 NAPROXEN SODIUM
11.3.5.2 NAPROXEN
11.3.5.3 KETOPROFEN
11.3.5.4 FENOPROFEN
11.3.5.5 OTHERS
11.3.6 BLOOD PRESSURE-LOWERING MEDICATIONS
11.3.6.1 BETA BLOCKERS
11.3.6.1.1 PROPRANAOLOL
11.3.6.1.2 TIMOLOL
11.3.6.1.3 OTHERS
11.3.6.2 CALCIUM-CHANNEL BLOCKERS
11.3.6.2.1 VERAPAMIL
11.3.6.2.2 NIMODIPINE
11.3.6.2.3 OTHERS
11.3.7 ANGIOTENSIN BLOCKERS: ACE-IS/ARBS
11.3.7.1 CANDESARTAN
11.3.7.2 TELMISARTAN
11.3.7.3 OTHERS
11.3.8 OTHERS
11.4 NON-PHARMACOLOGICAL THERAPIES
11.4.1 ACUPUNCTURE
11.4.2 BIOFEEDBACK TECHNIQUES
11.4.3 COGNITIVE BEHAVIOR THERAPY
11.4.4 MASSAGE
11.4.5 RELAXATION
11.4.6 OTHERS
11.5 DEVICES
11.5.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
11.5.2 OTHERS
12 GLOBAL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.3 PARENTERAL
12.4 NASAL SPRAYS
12.5 OTHERS
13 GLOBAL MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER
14 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPE
14.1 OVERVIEW
14.2 GENERIC
14.3 BRANDED
15 GLOBAL MIGRAINE TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOMECARE
15.5 OTHERS
16 GLOBAL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACIES
16.3 RETAIL PHARMACIES
16.4 ONLINE PHARMACIES
16.5 OTHERS
17 GLOBAL MIGRAINE TREATMENT MARKET, BY GEOGRAPHY
17.1 OVERVIEW
17.2 NORTH AMERICA
17.2.1 U.S.
17.2.2 CANADA
17.2.3 MEXICO
17.3 EUROPE
17.3.1 GERMANY
17.3.2 U.K.
17.3.3 FRANCE
17.3.4 ITALY
17.3.5 SPAIN
17.3.6 NETHERLANDS
17.3.7 RUSSIA
17.3.8 SWITZERLAND
17.3.9 BELGIUM
17.3.10 TURKEY
17.3.11 AUSTRIA
17.3.12 NORWAY
17.3.13 HUNGARY
17.3.14 LITHUANIA
17.3.15 IRELAND
17.3.16 POLAND
17.3.17 REST OF EUROPE
17.4 ASIA-PACIFIC
17.4.1 CHINA
17.4.2 JAPAN
17.4.3 INDIA
17.4.4 SOUTH KOREA
17.4.5 AUSTRALIA
17.4.6 SINGAPORE
17.4.7 INDONESIA
17.4.8 THAILAND
17.4.9 MALAYSIA
17.4.10 PHILIPPINES
17.4.11 VIETNAM
17.4.12 REST OF ASIA-PACIFIC
17.5 SOUTH AMERICA
17.5.1 BRAZIL
17.5.2 ARGENTINA
17.5.3 PERU
17.5.4 REST OF SOUTH AMERICA
17.6 MIDDLE EAST & AFRICA
17.6.1 SAUDI ARABIA
17.6.2 SOUTH AFRICA
17.6.3 UAE
17.6.4 ISRAEL
17.6.5 KUWAIT
17.6.6 EGYPT
17.6.7 REST OF MIDDLE EAST & AFRICA
18 GLOBAL MIGRAINE TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT ANALYSIS AND DATA BRIDGE MARKET RESEARCH ANALYSIS
19.1 SWOT ANALYSIS
19.1.1 STRENGTH
19.1.1.1 STRONG PRODUCT PORTFOLIO
19.1.1.2 GLOBAL COMMERCIAL PRESENCE IN EMERGING MARKETS
19.1.2 WEAKNESS
19.1.2.1 DEPENDENCY ON THIRD PARTIES FOR RESEARCH AND DEVELOPMENT
19.1.2.2 LITIGATION AND GOVERNMENT INVESTIGATION
19.1.3 OPPORTUNITY
19.1.3.1 EXPANDING BUSINESS THOROUGH THEIR SUBSIDIARIES
19.1.3.2 STRATEGIC INITIATIVES
19.1.4 THREAT
19.1.4.1 COMPETITIVE ENVIRONMENT
19.2 GLOBAL MIGRAINE TREATMENT MARKET: DBMR ANALYSIS
20 COMPANY PROFILE
20.1 AMGEN INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 ELI LILLY AND COMPANY
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 GLAXOSMITHKLINE PLC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 NOVARTIS AG
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BAYER AG
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 ALLERGAN
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ABBOTT
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENTS
20.8 ALLODYNIC THERAPEUTICS, LLC
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.9 AOBIOME
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENTS
20.1 ASTRAZENECA
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 BAUSCH HEALTH COMPANIES INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 BIOHAVEN PHARMACEUTICALS
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE ANALYSIS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENTS
20.15 CATALENT, INC
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 DR. REDDY’S LABORATORIES LTD.
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENTS
20.17 IMPEL NEUROPHARMA, INC.
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.18 LUNDBECK
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 NEURELIS, INC.
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENTS
20.21 OTSUKA PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF OTSUKA HOLDINGS CO., LTD.)
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENTS
20.22 PFIZER INC.
20.22.1 COMPANY SNAPSHOT
20.22.2 REVENUE ANALYSIS
20.22.3 PRODUCT PORTFOLIO
20.22.4 RECENT DEVELOPMENTS
20.23 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.23.1 COMPANY SNAPSHOT
20.23.2 REVENUE ANALYSIS
20.23.3 PRODUCT PORTFOLIO
20.23.4 RECENT DEVELOPMENTS
20.24 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)
20.24.1 COMPANY SNAPSHOT
20.24.2 REVENUE ANALYSIS
20.24.3 PRODUCT PORTFOLIO
20.24.4 RECENT DEVELOPMENTS
20.25 ZOSANO PHARMA CORPORATION
20.25.1 COMPANY SNAPSHOT
20.25.2 REVENUE ANALYSIS
20.25.3 PRODUCT PORTFOLIO
20.25.4 RECENT DEVELOPMENTS
21 CONCLUSION
22 QUESTIONNAIRE
23 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 GENERIC DRUGS FOR MIGRAINE TREATMENT
TABLE 2 PIPELINE DRUGS FOR MIGRAINE TREATMENT
TABLE 3 GLOBAL MIGRAINE TREATMENT MARKET, BY PIPELINE ANALYSIS
TABLE 4 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 5 GLOBAL EPISODIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 6 GLOBAL MIGRAINE WITH AURA IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 7 GLOBAL CHRONIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 8 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 9 GLOBAL MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 10 GLOBAL ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 11 GLOBAL ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 12 GLOBAL NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TRAETMENT, 2018-2027 (USD MILLION)
TABLE 13 GLOBAL TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 14 GLOBAL OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 15 GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 16 GLOBAL ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 17 GLOBAL ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 18 GLOBAL ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 19 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY TRATMENT, 2018-2027 (USD MILLION)
TABLE 20 GLOBAL PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 21 GLOBAL PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 22 GLOBAL ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 23 GLOBAL CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 24 GLOBAL SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 25 GLOBAL ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 26 GLOBAL NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 27 GLOBAL BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 28 GLOBAL BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 29 GLOBAL CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 30 GLOBAL ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 31 GLOBAL NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 32 GLOBAL NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 33 GLOBAL DEVICES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 34 GLOBAL DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 35 GLOBAL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 36 GLOBAL ORAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 37 GLOBAL PARENTERAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 38 GLOBAL NASAL SPRAYS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 39 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 40 GLOBAL MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 41 GLOBAL PRESCRIPTION IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 42 GLOBAL OVER THE COUNTER IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 43 GLOBAL MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 44 GLOBAL GENERIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 45 GLOBAL BRANDED IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 46 GLOBAL MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 47 GLOBAL HOSPITALS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 48 GLOBAL CLINICS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 49 GLOBAL HOMECARE IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 50 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 51 GLOBAL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 52 GLOBAL HOSPITAL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 53 GLOBAL RETAIL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 54 GLOBAL ONLINE PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 55 GLOBAL OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 56 GLOBAL MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 57 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 58 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 59 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 60 NORTH AMERICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 61 NORTH AMERICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 62 NORTH AMERICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 63 NORTH AMERICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 64 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 65 NORTH AMERICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 66 NORTH AMERICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 67 NORTH AMERICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 68 NORTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 69 NORTH AMERICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 70 NORTH AMERICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 71 NORTH AMERICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 72 NORTH AMERICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 73 NORTH AMERICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 74 NORTH AMERICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 75 NORTH AMERICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 76 NORTH AMERICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 77 NORTH AMERICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 78 NORTH AMERICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 79 NORTH AMERICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 80 NORTH AMERICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 81 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 82 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 83 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 84 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 85 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 86 U.S. MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 87 U.S. MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 88 U.S. ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 89 U.S. NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 90 U.S. TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 91 U.S. OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 92 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 93 U.S. ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 94 U.S. ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 95 U.S. ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 96 U.S. OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 97 U.S. PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 98 U.S. ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 99 U.S. CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)
TABLE 100 U.S. SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 101 U.S. ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 102 U.S. NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 103 U.S. BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 104 U.S. BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 105 U.S. CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 106 U.S. ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 107 U.S. NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 108 U.S. DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 109 U.S. MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 110 U.S. MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 111 U.S. MIGRAINE TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 112 U.S. MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 113 U.S. MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 114 CANADA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 115 CANADA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 116 CANADA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 117 CANADA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 118 CANADA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 119 CANADA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 120 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 121 CANADA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 122 CANADA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 123 CANADA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 124 CANADA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 125 CANADA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 126 CANADA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 127 CANADA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 128 CANADA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 129 CANADA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 130 CANADA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 131 CANADA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 132 CANADA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 133 CANADA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 134 CANADA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 135 CANADA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 136 CANADA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 137 CANADA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 138 CANADA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 139 CANADA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 140 CANADA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 141 CANADA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 142 MEXICO MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 143 MEXICO MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 144 MEXICO ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 145 MEXICO NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 146 MEXICO TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 147 MEXICO OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 148 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 149 MEXICO ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 150 MEXICO ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 151 MEXICO ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 152 MEXICO OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 153 MEXICO PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 154 MEXICO ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 155 MEXICO CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 156 MEXICO SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 157 MEXICO ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 158 MEXICO NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 159 MEXICO BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 160 MEXICO BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 161 MEXICO CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 162 MEXICO ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 163 MEXICO NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 164 MEXICO DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 165 MEXICO MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 166 MEXICO MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 167 MEXICO MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 168 MEXICO MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 169 MEXICO MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 170 EUROPE MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 171 EUROPE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 172 EUROPE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 173 EUROPE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 174 EUROPE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 175 EUROPE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 176 EUROPE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 177 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 178 EUROPE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 179 EUROPE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 180 EUROPE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 181 EUROPE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 182 EUROPE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 183 EUROPE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 184 EUROPE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 185 EUROPE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 186 EUROPE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 187 EUROPE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 188 EUROPE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 189 EUROPE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 190 EUROPE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 191 EUROPE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 192 EUROPE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 193 EUROPE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 194 EUROPE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 195 EUROPE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 196 EUROPE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 197 EUROPE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 198 EUROPE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 199 GERMANY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 200 GERMANY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 201 GERMANY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 202 GERMANY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 203 GERMANY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 204 GERMANY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 205 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 206 GERMANY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 207 GERMANY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 208 GERMANY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 209 GERMANY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 210 GERMANY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 211 GERMANY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 212 GERMANY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)
TABLE 213 GERMANY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 214 GERMANY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 215 GERMANY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 216 GERMANY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 217 GERMANY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 218 GERMANY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 219 GERMANY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 220 GERMANY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 221 EUROPE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 222 GERMANY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 223 GERMANY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 224 GERMANY MIGRAINE TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 225 GERMANY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 226 GERMANY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 227 U.K. MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 228 U.K. MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 229 U.K. ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 230 U.K. NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 231 U.K. TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 232 U.K. OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 233 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 234 U.K. ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 235 U.K. ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 236 U.K. ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 237 U.K. OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 238 U.K. PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 239 U.K. ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 240 U.K. CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 241 U.K. SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 242 U.K. ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 243 U.K. NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 244 U.K. BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 245 U.K. BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 246 U.K. CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 247 U.K. ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 248 U.K. NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 249 U.K. DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 250 U.K. MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 251 U.K. MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 252 U.K. MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 253 U.K. MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 254 U.K. MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 255 FRANCE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 256 FRANCE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 257 FRANCE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 258 FRANCE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 259 FRANCE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 260 FRANCE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 261 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 262 FRANCE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 263 FRANCE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 264 FRANCE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 265 FRANCE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 266 FRANCE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 267 FRANCE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 268 FRANCE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 269 FRANCE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 270 FRANCE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 271 FRANCE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 272 FRANCE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 273 FRANCE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 274 FRANCE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 275 FRANCE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 276 FRANCE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 277 FRANCE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 278 FRANCE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 279 FRANCE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 280 FRANCE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 281 FRANCE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 282 FRANCE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 283 ITALY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 284 ITALY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 285 ITALY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 286 ITALY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 287 ITALY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 288 ITALY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 289 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 290 ITALY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 291 ITALY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 292 ITALY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 293 ITALY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 294 ITALY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 295 ITALY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 296 ITALY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 297 ITALY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 298 ITALY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 299 ITALY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 300 ITALY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 301 ITALY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 302 ITALY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 303 ITALY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 304 ITALY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 305 ITALY DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 306 ITALY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 307 ITALY MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 308 ITALY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 309 ITALY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 310 ITALY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 311 SPAIN MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 312 SPAIN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 313 SPAIN ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 314 SPAIN NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 315 SPAIN TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 316 SPAIN OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 317 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 318 SPAIN ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 319 SPAIN ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 320 SPAIN ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 321 SPAIN OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 322 SPAIN PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 323 SPAIN ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 324 SPAIN CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 325 SPAIN SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 326 SPAIN ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 327 SPAIN NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 328 SPAIN BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 329 SPAIN BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 330 SPAIN CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 331 SPAIN ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 332 SPAIN NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 333 SPAIN DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 334 SPAIN MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 335 SPAIN MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 336 SPAIN MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 337 SPAIN MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 338 SPAIN MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 339 NETHERLANDS MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 340 NETHERLANDS MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 341 NETHERLANDS ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 342 NETHERLANDS NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 343 NETHERLANDS TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 344 NETHERLANDS OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 345 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 346 NETHERLANDS ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 347 NETHERLANDS ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 348 NETHERLANDS ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 349 NETHERLANDS OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 350 NETHERLANDS PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 351 NETHERLANDS ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 352 NETHERLANDS CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 353 NETHERLANDS SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 354 NETHERLANDS ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 355 NETHERLANDS NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 356 NETHERLANDS BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 357 NETHERLANDS BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 358 NETHERLANDS CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 359 NETHERLANDS ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 360 NETHERLANDS NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 361 NETHERLANDS DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 362 NETHERLANDS MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 363 NETHERLANDS MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 364 NETHERLANDS MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 365 NETHERLANDS MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 366 NETHERLANDS MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 367 RUSSIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 368 RUSSIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 369 RUSSIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 370 RUSSIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 371 RUSSIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 372 RUSSIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 373 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 374 RUSSIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 375 RUSSIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 376 RUSSIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 377 RUSSIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 378 RUSSIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 379 RUSSIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 380 RUSSIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 381 RUSSIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 382 RUSSIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 383 RUSSIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 384 RUSSIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 385 RUSSIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 386 RUSSIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 387 RUSSIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 388 RUSSIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 389 RUSSIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 390 RUSSIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 391 RUSSIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 392 RUSSIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 393 RUSSIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 394 RUSSIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 395 SWITZERLAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 396 SWITZERLAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 397 SWITZERLAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 398 SWITZERLAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 399 SWITZERLAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 400 SWITZERLAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 401 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 402 SWITZERLAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 403 SWITZERLAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 404 SWITZERLAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 405 SWITZERLAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 406 SWITZERLAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 407 SWITZERLAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 408 SWITZERLAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 409 SWITZERLAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 410 SWITZERLAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 411 SWITZERLAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 412 SWITZERLAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 413 SWITZERLAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 414 SWITZERLAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 415 SWITZERLAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 416 SWITZERLAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 417 SWITZERLAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 418 SWITZERLAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 419 SWITZERLAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 420 SWITZERLAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 421 SWITZERLAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 422 SWITZERLAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 423 BELGIUM MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 424 BELGIUM MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 425 BELGIUM ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 426 BELGIUM NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 427 BELGIUM TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 428 BELGIUM OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 429 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 430 BELGIUM ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 431 BELGIUM ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 432 BELGIUM ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 433 BELGIUM OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 434 BELGIUM PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 435 BELGIUM ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 436 BELGIUM CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 437 BELGIUM SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 438 BELGIUM ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 439 BELGIUM NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 440 BELGIUM BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 441 BELGIUM BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 442 BELGIUM CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 443 BELGIUM ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 444 BELGIUM NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 445 BELGIUM DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 446 BELGIUM MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 447 BELGIUM MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 448 BELGIUM MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 449 BELGIUM MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 450 BELGIUM MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 451 TURKEY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 452 TURKEY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 453 TURKEY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 454 TURKEY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 455 TURKEY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 456 TURKEY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 457 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 458 TURKEY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 459 TURKEY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 460 TURKEY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 461 TURKEY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 462 TURKEY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 463 TURKEY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 464 TURKEY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 465 TURKEY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 466 TURKEY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 467 TURKEY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 468 TURKEY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 469 TURKEY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 470 TURKEY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 471 TURKEY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 472 TURKEY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 473 TURKEY DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 474 TURKEY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 475 TURKEY MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 476 TURKEY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 477 TURKEY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 478 TURKEY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 479 AUSTRIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 480 AUSTRIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 481 AUSTRIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 482 AUSTRIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 483 AUSTRIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 484 AUSTRIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 485 AUSTRIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 486 AUSTRIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 487 AUSTRIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 488 AUSTRIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 489 AUSTRIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 490 AUSTRIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 491 AUSTRIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 492 AUSTRIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 493 AUSTRIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 494 AUSTRIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 495 AUSTRIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 496 AUSTRIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 497 AUSTRIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 498 AUSTRIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 499 AUSTRIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 500 AUSTRIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 501 AUSTRIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 502 AUSTRIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 503 AUSTRIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 504 AUSTRIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 505 AUSTRIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 506 AUSTRIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 507 NORWAY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 508 NORWAY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 509 NORWAY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 510 NORWAY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 511 NORWAY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 512 NORWAY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 513 NORWAY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 514 NORWAY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 515 NORWAY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 516 NORWAY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 517 NORWAY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 518 NORWAY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 519 NORWAY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 520 NORWAY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 521 NORWAY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 522 NORWAY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 523 NORWAY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 524 NORWAY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 525 NORWAY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 526 NORWAY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 527 NORWAY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 528 NORWAY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 529 NORWAY DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 530 NORWAY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 531 NORWAY MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 532 NORWAY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 533 NORWAY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 534 NORWAY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 535 HUNGARY MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 536 HUNGARY MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 537 HUNGARY ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 538 HUNGARY NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 539 HUNGARY TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 540 HUNGARY OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 541 HUNGARY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 542 HUNGARY ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 543 HUNGARY ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 544 HUNGARY ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 545 HUNGARY OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 546 HUNGARY PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 547 HUNGARY ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 548 HUNGARY CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 549 HUNGARY SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 550 HUNGARY ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 551 HUNGARY NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 552 HUNGARY BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 553 HUNGARY BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 554 HUNGARY CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 555 HUNGARY ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 556 HUNGARY NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 557 HUNGARY DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 558 HUNGARY MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 559 HUNGARY MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 560 HUNGARY MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 561 HUNGARY MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 562 HUNGARY MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 563 LITHUANIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 564 LITHUANIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 565 LITHUANIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 566 LITHUANIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 567 LITHUANIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 568 LITHUANIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 569 LITHUANIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 570 LITHUANIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 571 LITHUANIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 572 LITHUANIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 573 LITHUANIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 574 LITHUANIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 575 LITHUANIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 576 LITHUANIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 577 LITHUANIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 578 LITHUANIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 579 LITHUANIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 580 LITHUANIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 581 LITHUANIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 582 LITHUANIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 583 LITHUANIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 584 LITHUANIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 585 LITHUANIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 586 LITHUANIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 587 LITHUANIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 588 LITHUANIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 589 LITHUANIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 590 LITHUANIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 591 IRELAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 592 IRELAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 593 IRELAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 594 IRELAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 595 IRELAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 596 IRELAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 597 IRELAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 598 IRELAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 599 IRELAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 600 IRELAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 601 IRELAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 602 IRELAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 603 IRELAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 604 IRELAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 605 IRELAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 606 IRELAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 607 IRELAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 608 IRELAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 609 IRELAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 610 IRELAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 611 IRELAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 612 IRELAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 613 IRELAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 614 IRELAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 615 IRELAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 616 IRELAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 617 IRELAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 618 IRELAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 619 POLAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 620 POLAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 621 POLAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 622 POLAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 623 POLAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 624 POLAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 625 POLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 626 POLAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 627 POLAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 628 POLAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 629 POLAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 630 POLAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 631 POLAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 632 POLAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 633 POLAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 634 POLAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 635 POLAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 636 POLAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 637 POLAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 638 POLAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 639 POLAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 640 POLAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 641 POLAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 642 POLAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 643 POLAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 644 POLAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 645 POLAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 646 POLAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 647 REST OF EUROPE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 648 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 649 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 650 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 651 ASIA-PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 652 ASIA-PACIFIC NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 653 ASIA-PACIFIC TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 654 ASIA-PACIFIC OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 655 ASIA-PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 656 ASIA-PACIFIC ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 657 ASIA-PACIFIC ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 658 ASIA-PACIFIC ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 659 ASIA-PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 660 ASIA-PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 661 ASIA-PACIFIC ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 662 ASIA-PACIFIC CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 663 ASIA-PACIFIC SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 664 ASIA-PACIFIC ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 665 ASIA-PACIFIC NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 666 ASIA-PACIFIC BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 667 ASIA-PACIFIC BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 668 ASIA-PACIFIC CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 669 ASIA-PACIFIC ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 670 ASIA-PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 671 ASIA-PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 672 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 673 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 674 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 675 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 676 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 677 CHINA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 678 CHINA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 679 CHINA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 680 CHINA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 681 CHINA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 682 CHINA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 683 CHINA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 684 CHINA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 685 CHINA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 686 CHINA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 687 CHINA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 688 CHINA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 689 CHINA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 690 CHINA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)
TABLE 691 CHINA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 692 CHINA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 693 CHINA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 694 CHINA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 695 CHINA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 696 CHINA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 697 CHINA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 698 CHINA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 699 CHINA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 700 CHINA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 701 CHINA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 702 CHINA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 703 CHINA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 704 CHINA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 705 JAPAN MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 706 JAPAN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 707 JAPAN ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 708 JAPAN NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 709 JAPAN TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 710 JAPAN OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 711 JAPAN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 712 JAPAN ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 713 JAPAN ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 714 JAPAN ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 715 JAPAN OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 716 JAPAN PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 717 JAPAN ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 718 JAPAN CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 719 JAPAN SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 720 JAPAN ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 721 JAPAN NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 722 JAPAN BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 723 JAPAN BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 724 JAPAN CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 725 JAPAN ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 726 JAPAN NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 727 JAPAN DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 728 JAPAN MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 729 JAPAN MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 730 JAPAN MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 731 JAPAN MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 732 JAPAN MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 733 INDIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 734 INDIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 735 INDIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 736 INDIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 737 INDIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 738 INDIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 739 INDIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 740 INDIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 741 INDIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 742 INDIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 743 INDIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 744 INDIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 745 INDIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 746 INDIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 747 INDIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 748 INDIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 749 INDIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 750 INDIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 751 INDIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 752 INDIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 753 INDIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 754 INDIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 755 INDIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 756 INDIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 757 INDIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 758 INDIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 759 INDIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 760 INDIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 761 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 762 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 763 SOUTH KOREA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 764 SOUTH KOREA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 765 SOUTH KOREA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 766 SOUTH KOREA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 767 SOUTH KOREA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 768 SOUTH KOREA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 769 SOUTH KOREA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 770 SOUTH KOREA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 771 SOUTH KOREA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 772 SOUTH KOREA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 773 SOUTH KOREA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 774 SOUTH KOREA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 775 SOUTH KOREA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 776 SOUTH KOREA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 777 SOUTH KOREA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 778 SOUTH KOREA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 779 SOUTH KOREA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 780 SOUTH KOREA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 781 SOUTH KOREA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 782 SOUTH KOREA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 783 SOUTH KOREA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 784 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 785 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 786 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 787 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 788 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 789 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 790 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 791 AUSTRALIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 792 AUSTRALIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 793 AUSTRALIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 794 AUSTRALIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 795 AUSTRALIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 796 AUSTRALIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 797 AUSTRALIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 798 AUSTRALIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 799 AUSTRALIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 800 AUSTRALIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 801 AUSTRALIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 802 AUSTRALIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 803 AUSTRALIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 804 AUSTRALIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 805 AUSTRALIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 806 AUSTRALIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 807 AUSTRALIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 808 AUSTRALIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 809 AUSTRALIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 810 AUSTRALIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 811 AUSTRALIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 812 AUSTRALIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 813 AUSTRALIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 814 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 815 AUSTRALIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 816 AUSTRALIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 817 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 818 SINGAPORE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 819 SINGAPORE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 820 SINGAPORE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 821 SINGAPORE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 822 SINGAPORE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 823 SINGAPORE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 824 SINGAPORE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 825 SINGAPORE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 826 SINGAPORE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 827 SINGAPORE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 828 SINGAPORE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 829 SINGAPORE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 830 SINGAPORE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 831 SINGAPORE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 832 SINGAPORE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 833 SINGAPORE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 834 SINGAPORE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 835 SINGAPORE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 836 SINGAPORE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 837 SINGAPORE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 838 SINGAPORE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 839 SINGAPORE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 840 SINGAPORE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 841 SINGAPORE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 842 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 843 SINGAPORE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 844 SINGAPORE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 845 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 846 INDONESIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 847 INDONESIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 848 INDONESIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 849 INDONESIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 850 INDONESIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 851 INDONESIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 852 INDONESIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 853 INDONESIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 854 INDONESIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 855 INDONESIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 856 INDONESIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 857 INDONESIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 858 INDONESIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 859 INDONESIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 860 INDONESIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 861 INDONESIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 862 INDONESIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 863 INDONESIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 864 INDONESIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 865 INDONESIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 866 INDONESIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 867 INDONESIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 868 INDONESIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 869 INDONESIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 870 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 871 INDONESIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 872 INDONESIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 873 THAILAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 874 THAILAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 875 THAILAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 876 THAILAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 877 THAILAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 878 THAILAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 879 THAILAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 880 THAILAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 881 THAILAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 882 THAILAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 883 THAILAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 884 THAILAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 885 THAILAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 886 THAILAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 887 THAILAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 888 THAILAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 889 THAILAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 890 THAILAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 891 THAILAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 892 THAILAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 893 THAILAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 894 THAILAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 895 THAILAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 896 THAILAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 897 THAILAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 898 THAILAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 899 THAILAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 900 THAILAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 901 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 902 MALAYSIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 903 MALAYSIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 904 MALAYSIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 905 MALAYSIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 906 MALAYSIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 907 MALAYSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 908 MALAYSIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 909 MALAYSIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 910 MALAYSIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 911 MALAYSIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 912 MALAYSIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 913 MALAYSIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 914 MALAYSIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 915 MALAYSIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 916 MALAYSIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 917 MALAYSIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 918 MALAYSIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 919 MALAYSIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 920 MALAYSIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 921 MALAYSIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 922 MALAYSIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 923 MALAYSIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 924 MALAYSIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 925 MALAYSIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 926 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 927 MALAYSIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 928 MALAYSIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 929 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 930 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 931 PHILIPPINES ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 932 PHILIPPINES NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 933 PHILIPPINES TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 934 PHILIPPINES OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 935 PHILIPPINES NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 936 PHILIPPINES ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 937 PHILIPPINES ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 938 PHILIPPINES ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 939 PHILIPPINES OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 940 PHILIPPINES PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 941 PHILIPPINES ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 942 PHILIPPINES CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 943 PHILIPPINES SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 944 PHILIPPINES ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 945 PHILIPPINES NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 946 PHILIPPINES BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 947 PHILIPPINES BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 948 PHILIPPINES CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 949 PHILIPPINES ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 950 PHILIPPINES NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 951 PHILIPPINES DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 952 PHILIPPINES MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 953 PHILIPPINES MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 954 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 955 PHILIPPINES MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 956 PHILIPPINES MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 957 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 958 VIETNAM MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 959 VIETNAM ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 960 VIETNAM NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 961 VIETNAM TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 962 VIETNAM OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 963 VIETNAM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 964 VIETNAM ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 965 VIETNAM ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 966 VIETNAM ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 967 VIETNAM OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 968 VIETNAM PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 969 VIETNAM ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 970 VIETNAM CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 971 VIETNAM SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 972 VIETNAM ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 973 VIETNAM NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 974 VIETNAM BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 975 VIETNAM BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 976 VIETNAM CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 977 VIETNAM ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 978 VIETNAM NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 979 VIETNAM DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 980 VIETNAM MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 981 VIETNAM MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 982 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 983 VIETNAM MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 984 VIETNAM MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 985 REST OF ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 986 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 987 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 988 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 989 SOUTH AMERICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 990 SOUTH AMERICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 991 SOUTH AMERICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 992 SOUTH AMERICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 993 SOUTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 994 SOUTH AMERICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 995 SOUTH AMERICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 996 SOUTH AMERICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 997 SOUTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 998 SOUTH AMERICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 999 SOUTH AMERICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1000 SOUTH AMERICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1001 SOUTH AMERICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1002 SOUTH AMERICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1003 SOUTH AMERICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1004 SOUTH AMERICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1005 SOUTH AMERICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1006 SOUTH AMERICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1007 SOUTH AMERICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1008 SOUTH AMERICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1009 SOUTH AMERICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1010 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1011 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1012 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1013 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1014 SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1015 BRAZIL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1016 BRAZIL MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1017 BRAZIL ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1018 BRAZIL NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1019 BRAZIL TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1020 BRAZIL OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1021 BRAZIL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1022 BRAZIL ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1023 BRAZIL ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1024 BRAZIL ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1025 BRAZIL OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1026 BRAZIL PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1027 BRAZIL ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1028 BRAZIL CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)
TABLE 1029 BRAZIL SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1030 BRAZIL ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1031 BRAZIL NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1032 BRAZIL BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1033 BRAZIL BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1034 BRAZIL CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1035 BRAZIL ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1036 BRAZIL NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1037 SOUTH AMERICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1038 BRAZIL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1039 BRAZIL MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1040 BRAZIL MIGRAINE TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 1041 BRAZIL MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1042 BRAZIL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1043 ARGENTINA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1044 ARGENTINA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1045 ARGENTINA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1046 ARGENTINA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1047 ARGENTINA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1048 ARGENTINA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1049 ARGENTINA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1050 ARGENTINA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1051 ARGENTINA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1052 ARGENTINA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1053 ARGENTINA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1054 ARGENTINA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1055 ARGENTINA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1056 ARGENTINA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1057 ARGENTINA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1058 ARGENTINA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1059 ARGENTINA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1060 ARGENTINA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1061 ARGENTINA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1062 ARGENTINA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1063 ARGENTINA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1064 ARGENTINA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1065 ARGENTINA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1066 ARGENTINA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1067 ARGENTINA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1068 ARGENTINA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1069 ARGENTINA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1070 ARGENTINA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1071 PERU MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1072 PERU MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1073 PERU ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1074 PERU NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1075 PERU TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1076 PERU OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1077 PERU NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1078 PERU ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1079 PERU ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1080 PERU ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1081 PERU OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1082 PERU PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1083 PERU ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1084 PERU CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1085 PERU SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1086 PERU ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1087 PERU NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1088 PERU BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1089 PERU BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1090 PERU CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1091 PERU ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1092 PERU NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1093 PERU DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1094 PERU MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1095 PERU MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1096 PERU MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1097 PERU MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1098 PERU MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1099 REST OF SOUTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1100 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 1101 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1102 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1103 MIDDLE EAST & AFRICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1104 MIDDLE EAST & AFRICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1105 MIDDLE EAST & AFRICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1106 MIDDLE EAST & AFRICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1107 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1108 MIDDLE EAST & AFRICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1109 MIDDLE EAST & AFRICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1110 MIDDLE EAST & AFRICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1111 MIDDLE EAST & AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1112 MIDDLE EAST & AFRICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1113 MIDDLE EAST & AFRICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1114 MIDDLE EAST & AFRICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1115 MIDDLE EAST & AFRICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1116 MIDDLE EAST & AFRICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1117 MIDDLE EAST & AFRICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1118 MIDDLE EAST & AFRICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1119 MIDDLE EAST & AFRICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1120 MIDDLE EAST & AFRICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1121 MIDDLE EAST & AFRICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1122 MIDDLE EAST & AFRICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1123 MIDDLE EAST & AFRICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1124 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1125 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1126 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1127 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1128 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1129 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1130 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1131 SAUDI ARABIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1132 SAUDI ARABIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1133 SAUDI ARABIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1134 SAUDI ARABIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1135 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1136 SAUDI ARABIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1137 SAUDI ARABIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1138 SAUDI ARABIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1139 SAUDI ARABIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1140 SAUDI ARABIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1141 SAUDI ARABIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1142 SAUDI ARABIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1143 SAUDI ARABIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1144 SAUDI ARABIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1145 SAUDI ARABIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1146 SAUDI ARABIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1147 SAUDI ARABIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1148 SAUDI ARABIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1149 SAUDI ARABIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1150 SAUDI ARABIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1151 SAUDI ARABIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1152 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1153 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1154 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1155 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1156 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1157 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1158 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1159 SOUTH AFRICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1160 SOUTH AFRICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1161 SOUTH AFRICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1162 SOUTH AFRICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1163 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1164 SOUTH AFRICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1165 SOUTH AFRICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1166 SOUTH AFRICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1167 SOUTH AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1168 SOUTH AFRICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1169 SOUTH AFRICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1170 SOUTH AFRICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1171 SOUTH AFRICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1172 SOUTH AFRICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1173 SOUTH AFRICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1174 SOUTH AFRICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1175 SOUTH AFRICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1176 SOUTH AFRICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLIONX`)
TABLE 1177 SOUTH AFRICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1178 SOUTH AFRICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1179 SOUTH AFRICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1180 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1181 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1182 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1183 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1184 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1185 UAE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1186 UAE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1187 UAE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1188 UAE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1189 UAE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1190 UAE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1191 UAENONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1192 UAE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1193 UAE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1194 UAE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1195 UAE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1196 UAE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1197 UAE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1198 UAE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1199 UAE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1200 UAE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1201 UAE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1202 UAE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1203 UAE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1204 UAE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1205 UAE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1206 UAE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1207 UAE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1208 UAE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1209 UAE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1210 UAE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1211 UAE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1212 UAE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1213 ISRAEL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1214 ISRAEL MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1215 ISRAEL ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1216 ISRAEL NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1217 ISRAEL TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1218 ISRAEL OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1219 ISRAELNONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1220 ISRAEL ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1221 ISRAEL ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1222 ISRAEL ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1223 ISRAEL OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1224 ISRAEL PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1225 ISRAEL ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1226 ISRAEL CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1227 ISRAEL SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1228 ISRAEL ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1229 ISRAEL NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1230 ISRAEL BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1231 ISRAEL BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1232 ISRAEL CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1233 ISRAEL ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1234 ISRAEL NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1235 ISRAEL DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1236 ISRAEL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1237 ISRAEL MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1238 ISRAEL MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1239 ISRAEL MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1240 ISRAEL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1241 KUWAIT MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1242 KUWAIT MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1243 KUWAIT ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1244 KUWAIT NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1245 KUWAIT TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1246 KUWAIT OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1247 KUWAITNONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1248 KUWAIT ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1249 KUWAIT ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1250 KUWAIT ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1251 KUWAIT OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1252 KUWAIT PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1253 KUWAIT ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1254 KUWAIT CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1255 KUWAIT SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1256 KUWAIT ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1257 KUWAIT NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1258 KUWAIT BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1259 KUWAIT BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1260 KUWAIT CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1261 KUWAIT ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1262 KUWAIT NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1263 KUWAIT DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1264 KUWAIT MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1265 KUWAIT MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1266 KUWAIT MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1267 KUWAIT MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1268 KUWAIT MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1269 EGYPT MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1270 EGYPT MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1271 EGYPT ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1272 EGYPT NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1273 EGYPT TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)
TABLE 1274 EGYPT OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1275 EGYPTNONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1276 EGYPT ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1277 EGYPT ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1278 EGYPT ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1279 EGYPT OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1280 EGYPT PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1281 EGYPT ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1282 EGYPT CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1283 EGYPT SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1284 EGYPT ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1285 EGYPT NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1286 EGYPT BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1287 EGYPT BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1288 EGYPT CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1289 EGYPT ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1290 EGYPT NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1291 EGYPT DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 1292 EGYPT MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 1293 EGYPT MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 1294 EGYPT MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 1295 EGYPT MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 1296 EGYPT MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 1297 REST OF MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 1298 SUBSIDIARIES OF JANSSEN GLOBAL SERVICES, LLC
List of Figure
LIST OF FIGURES
FIGURE 1 GLOBAL MIGRAINE TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL MIGRAINE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 GLOBAL MIGRAINE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL MIGRAINE TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL MIGRAINE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL MIGRAINE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL MIGRAINE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL MIGRAINE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL MIGRAINE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL MIGRAINE TREATMENT MARKET
FIGURE 11 RESULT OF PREVALENCE OF MIGRAINE FROM ONE YEAR STUDY
FIGURE 12 GLOBAL MIGRAINE TREATMENT MARKET: SEGMENTATION
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MIGRAINE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 14 INCREASING PREVALNCE OF MIGRAINE AND DEVELOPMENT OF NOVEL DRUGS IS DRIVING THE GLOBAL MIGRAINE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 15 EPISODIC IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MIGRAINE TREATMENT MARKET IN 2020 & 2027
FIGURE 16 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN GLOBAL MIGRAINE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 17 GLOBAL PREVALENCE OF MIGRAINE TREATMENT (2018)
FIGURE 18 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, 2019
FIGURE 19 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, 2019-2027 (USD MILLION)
FIGURE 20 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, CAGR (2020-2027)
FIGURE 21 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, LIFELINE CURVE
FIGURE 22 GLOBAL MIGRAINE TREATMENT MARKET: BY TREATMENT, 2019
FIGURE 23 GLOBAL MIGRAINE TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)
FIGURE 24 GLOBAL MIGRAINE TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)
FIGURE 25 GLOBAL MIGRAINE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 GLOBAL MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 27 GLOBAL MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 28 GLOBAL MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 29 GLOBAL MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 GLOBAL MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, 2019
FIGURE 31 GLOBAL MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, 2019-2027 (USD MILLION)
FIGURE 32 GLOBAL MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, CAGR (2020-2027)
FIGURE 33 GLOBAL MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 34 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPE, 2019
FIGURE 35 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION)
FIGURE 36 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 37 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 38 GLOBAL MIGRAINE TREATMENT MARKET: BY END USER, 2019
FIGURE 39 GLOBAL MIGRAINE TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 40 GLOBAL MIGRAINE TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 41 GLOBAL MIGRAINE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 GLOBAL MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 43 GLOBAL MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 44 GLOBAL MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 45 GLOBAL MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 GLOBAL MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 47 GLOBAL MIGRAINE TREATMENT MARKET: BY REGION (2019)
FIGURE 48 GLOBAL MIGRAINE TREATMENT MARKET: BY REGION (2020 & 2027)
FIGURE 49 GLOBAL MIGRAINE TREATMENT MARKET: BY REGION (2019 & 2027)
FIGURE 50 GLOBAL MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)
FIGURE 51 NORTH AMERICA MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 52 NORTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 53 NORTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 54 NORTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 55 NORTH AMERICA MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)
FIGURE 56 EUROPE MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 57 EUROPE MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 58 EUROPE MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 59 EUROPE MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 60 EUROPE MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)
FIGURE 61 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 62 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 63 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 64 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 65 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)
FIGURE 66 SOUTH AMERICA MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 67 SOUTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 68 SOUTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 69 SOUTH AMERICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 70 SOUTH AMERICA MIGRAINE TREATMENT MARKET: BY TREATMENT (2020-2027)
FIGURE 71 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 72 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 73 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 74 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 75 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)
FIGURE 76 GLOBAL MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)
FIGURE 77 NORTH AMERICA MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)
FIGURE 78 EUROPE MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)
FIGURE 79 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
